The levels of macrophage migration inhibitory factor as an indicator of disease activity and severity in adult-onset Still's disease

Clinical Biochemistry

Volumn 41, Issue 7-8, 2008, Pages 519-524

  Zou, Yu Qiong ^a   Lu, Liang Jing ^a   Li, Shu Jie ^a   Zeng, Ting ^a   Wang, Xiao Dong ^a   Bao, Chun De ^a   Chen, Shun Le ^a   Yang, Cheng De ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adult onset Still's disease; Macrophage migration inhibitory factor

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; MACROPHAGE MIGRATION INHIBITION FACTOR; METHOTREXATE; PREDNISONE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; INFECTION; JUVENILE RHEUMATOID ARTHRITIS; LEUKOCYTE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MYALGIA; NEOPLASM; PLEURISY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; SORE THROAT; SPLENOMEGALY; T LYMPHOCYTE;

ADULT; BIOLOGICAL MARKERS; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; STILL'S DISEASE, ADULT-ONSET; UP-REGULATION;

EID: 41849084435     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2008.01.008     Document Type: Article

References (37)

1. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56 (1966) 72-77
2. Bloom B.R., and Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153 (1966) 80-82
3. Calandra T., and Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3 (2003) 791-800
4. Onodera S., Suzuki K., Matsuno T., Kaneda K., Takagi M., and Nishihira J. Macrophage migration inhibitory factor induces phagocytosis of foreign particles by macrophages in autocrine and paracrine fashion. Immunology 92 (1997) 131-137
5. Bacher M., Metz C.N., Calandra T., et al. An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93 (1996) 7849-7854
6. Bywaters E.G. Still's disease in the adult. Ann Rheum Dis 30 (1971) 121-133
7. Magadur-Joly G., Billaud E., Barrier J.H., et al. Epidemiology of adult Still's disease: estimate of the incidence by a retrospective study in West France. Ann Rheum Dis 54 (1995) 587-590
8. Wakai K., Ohta A., Tamakoshi A., et al. Estimated prevalence and incidence of adult Still's disease: findings by a nationwide epidemiological survey in Japan. J Epidemiol 7 (1997) 221-225
9. Pouchot J., Sampalis J.S., Beaudet F., et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine(Baltimore) 70 (1991) 118-136
10. Efthimiou P., and Georgy S. Pathogenesis and management of adult-onset Still's disease. Semin Arthritis Rheum 36 (2006) 144-152
11. Calandra T., Bernhagen J., Metz C.N., et al. MIF as a glucocorticoid-induced modulator of cytokine production. Nature 377 (1995) 68-71
12. Lehmann L.E., Novender U., Schroeder S., et al. Plasma levels of macrophage migration inhibitory factor are elevated in patients with severe sepsis. Intensive Care Med 27 (2001) 1412-1415
13. Donnelly S.C., Haslett C., Reid P.T., et al. Regulatory role for macrophage migration inhibitory factor in acute respiratory distress syndrome. Nat Med 3 (1997) 320-323
14. Morand E.F., Leech M., Weedon H., Metz C., Bucala R., and Smith M.D. Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford) 41 (2002) 558-562
15. Foote A., Briganti E.M., Kipen Y., Santos L., Leech M., and Morand E.F. Macrophage migration inhibitory factor in systemic lupus erythematosus. J Rheumatol 31 (2004) 268-273
16. Meazza C., Travaglino P., Pignatti P., et al. Macrophage migration inhibitory factor in patients with juvenile idiopathic arthritis. Arthritis Rheum 46 (2002) 232-237
17. Yamaguchi M., Ohta A., Tsunematsu T., et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol 19 (1992) 424-430
18. Lehmann L.E., Weber S.U., Fuchs D., et al. Intracellular detection of macrophage migration inhibitory factor in peripheral blood leukocytes. Free Radic Biol Med 38 (2005) 1170-1179
19. Hoshino T., Ohta A., Yang D., et al. Elevated serum interleukin 6, interferon-gamma, and tumor necrosis factor-alpha levels in patients with adult Still's disease. J Rheumatol 25 (1998) 396-398
20. Fujii T., Nojima T., Yasuoka H., et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease. Association with chronic articular disease. Rheumatology (Oxford) 40 (2001) 1398-1404
21. Lue H., Kleemann R., Calandra T., Roger T., and Bernhagen J. Macrophage migration inhibitory factor (MIF): mechanisms of action and role in disease. Microbes Infect 4 (2002) 449-460
22. Efthimiou P., Paik P.K., and Bielory L. Diagnosis and management of adult onset Still's disease. Ann Rheum Dis 65 (2006) 564-572
23. Isidori A.M., Kaltsas G.A., Korbonits M., et al. Response of serum macrophage migration inhibitory factor levels to stimulation or suppression of the hypothalamo-pituitary-adrenal axis in normal subjects and patients with Cushing's disease. J Clin Endocrinol Metab 87 (2002) 1834-1840
24. Wilckens T., and De Rijk R. Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 18 (1997) 418-424
25. Leech M., Metz C., Santos L., et al. Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 41 (1998) 910-917
26. Santos L., Hall P., Metz C., and Bucala R Morand E.F. Role of macrophage migration inhibitory factor (MIF) in murine antigen-induced arthritis: interaction with glucocorticoids. Clin Exp Immunol 123 (2001) 309-314
27. Ichiyama H., Onodera S., Nishihira J., et al. Inhibition of joint inflammation and destruction induced by anti-type II collagen antibody/lipopolysaccharide (LPS)-induced arthritis in mice due to deletion of macrophage migration inhibitory factor (MIF). Cytokine 26 (2004) 187-194
28. Onodera S., Tanji H., Suzuki K., et al. High expression of macrophage migration inhibitory factor in the synovial tissues of rheumatoid joints. Cytokine 11 (1999) 163-167
29. Santos L.L., and Morand E.F. The role of macrophage migration inhibitory factor in the inflammatory immune response and rheumatoid arthritis. Wien Med Wochenschr 156 (2006) 11-18
30. De Jong Y.P., Abadia-Molina A.C., Satoskar A.R., et al. Development of chronic colitis is dependent on the cytokine MIF. Nat Immunol 2 (2001) 1061-1066
31. Chen D.Y., Lan J.L., Lin F.J., Hsieh T.Y., and Wen M.C. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis 63 (2004) 1300-1306
32. Choi J.H., Suh C.H., Lee Y.M., et al. Serum cytokine profiles in patients with adult onset Still's disease. J Rheumatol 30 (2003) 2422-2427
33. Wheelhouse N.M., Dowidar N., Dejong C.H., et al. The effects of macrophage migratory inhibitory factor on acute-phase protein production in primary human hepatocytes. Int J Mol Med 18 (2006) 957-961
34. Bernhagen J., Calandra T., Mitchell R., et al. MIF is a pituitary derived cytokine that potentiates lethal endotoxaemia. Nature 365 (1993) 756-759
35. Fautrel B. Ferritin levels in adult Still's disease: any sugar?. Joint Bone Spine 69 (2002) 355-357
36. Matsui K., Tsuchida T., Hiroishi K., et al. High serum level of macrophage-colony stimulating factor (M-CSF) in adult-onset Still's disease. Rheumatology (Oxford) 38 (1999) 477-478
37. Kleemann R., Hausser A., Geiger G., et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 408 (2000) 211-216